Ticker Details
Alkermes plc Ordinary Shares Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.
IPO Date:	August 1, 1991
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$8.11B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.53 | 1.99%
Avg Daily Range (30 D):	$0.94 | 1.86%
Avg Daily Range (90 D):	$0.90 | 2.04%

Institutional Daily Volume
Avg Daily Volume:	1.1M
Avg Daily Volume (30 D):	1.21M
Avg Daily Volume (90 D):	1.51M

Trade Size
Avg Trade Size (Sh.):	112
Avg Trade Size (Sh.) (30 D):	59
Avg Trade Size (Sh.) (90 D):	62

Institutional Trades
Total Institutional Trades:	14,737
Avg Institutional Trade:	$2.66M
Avg Institutional Trade (30 D):	$5.18M
Avg Institutional Trade (90 D):	$4.78M
Avg Institutional Trade Volume:	.09M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$5.77M
Avg Closing Trade (30 D):	$16.74M
Avg Closing Trade (90 D):	$19.17M
Avg Closing Volume:	189.54K

News

Jun 8, 2026 @ 5:00 PM Alcohol Use Disorder Market Set to Expand at a 12.... Source: Delveinsight

Feb 23, 2026 @ 3:26 PM Viridian Therapeutics Stock Up 75%, but One Fund J... Source: Jonathan Ponciano

Feb 23, 2026 @ 3:18 PM Spyre Therapeutics Stock Surges This Past Year as ... Source: Jonathan Ponciano

Feb 10, 2026 @ 9:05 PM Avadel Pharmaceuticals Announces Outcome of the Co... Source: Globe Newswire

Jan 12, 2026 @ 9:05 PM Avadel Pharmaceuticals Announces that Avadel Share... Source: Globe Newswire

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$.4	$	$-.4
Diluted EPS	$.38	$	$-.4
Revenue	$1.67B	$496.01M	$392.91M
Gross Profit	$1.41B	$397.9M	$331.33M
Net Income / Loss	$66.12M	$.5M	$-66.48M
Operating Income / Loss	$117.26M	$18.35M	$-48.28M
Cost of Revenue	$257.49M	$98.11M	$61.58M
Net Cash Flow	$-9.67M	$159.98M	$-768.22M
PE Ratio

Splits
May 15, 2000	2:1